MyFinsight
Home
Blog
About
Cash and cash
equivalents
$138,343K
(446.88%↑ Y/Y)
Prepaid expenses and
other current assets
$4,062K
(0.30%↑ Y/Y)
Restricted cash and cash
equivalents
$100K
(0.00%↑ Y/Y)
Total current assets
$142,505K
(383.94%↑ Y/Y)
Goodwill
$1,914K
(0.00%↑ Y/Y)
Operating lease
right-of-use assets
$710K
(3.95%↑ Y/Y)
Deposits and other assets
$253K
(-3.07%↓ Y/Y)
Total assets
$145,382K
(350.03%↑ Y/Y)
Total liabilities and
stockholders equity
$145,382K
(350.03%↑ Y/Y)
Total stockholders
equity
$137,656K
(426.43%↑ Y/Y)
Total liabilities
$7,726K
(25.50%↑ Y/Y)
Accumulated deficit
-$293,000K
(-12.46%↓ Y/Y)
Additional paid-in capital
$430,636K
(50.22%↑ Y/Y)
Total current
liabilities
$7,569K
(26.17%↑ Y/Y)
Operating lease
liabilities, non-current
$157K
(0.00%↑ Y/Y)
Common stock,
0.0001par value...
$20K
(100.00%↑ Y/Y)
Accrued expenses and
other current...
$3,903K
(87.37%↑ Y/Y)
Accounts payable
$3,086K
(-7.49%↓ Y/Y)
Operating lease
liabilities
$580K
(0.00%↑ Y/Y)
Back
Back
Balance Sheet
SELLAS Life Sciences Group, Inc. (SLS)
SELLAS Life Sciences Group, Inc. (SLS)
source: myfinsight.com